Dr. Reddy’s Laboratories announces the launch of Desmopressin Acetate Injection USP

Wednesday May 6, 2020 at 1:40 pm

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Desmopressin Acetate Injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic equivalent generic version of DDAVP (desmopressin acetate) Injection, 4 mcg/mL, approved by the U.S. Food and Drug Administration (USFDA). The DDAVP (desmopressin acetate) Injection USP brand and the generic market had U.S. sales of approximately $20.9 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health*. Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories, commented, “The launch of Desmopressin Injection demonstrates a strong, growing collaboration with SunGen Pharma. We look forward to future opportunities with this company.” Isaac Liu, Ph.D., Co-CEO of SunGen, stated, “We are pleased to be working with Dr. Reddy’s for this launch. The launch of Desmopressin demonstrates our strong development capabilities. We look forward to collaborating further to bring specialty pharmaceutical drugs to the markets around the world.” Dr. Reddy’s Desmopressin Acetate Injection USP, 4 mcg/mL is available in a carton of ten 1 mL singledose ampules.

Releted Blog
  • Benefits of High-Intensity Interval Training workout

    In the realm of fitness, High-Intensity Interval Training (HIIT) has emerged as a revolutionary approach to exercise. This intense yet time-efficient ...

  • Everything Around Mental Wellness

    Introduction In today's fast-paced and demanding world, mental health has emerged as a critical aspect of overall well-being. The stigma surrounding ...

  • Health Benefits of Resistance Training

    In the pursuit of a healthier and more fulfilling life, exercise plays a pivotal role. Among the diverse forms of exercise, resistance training stands...